COVID-19 is a moving target for clinical trials: as the outbreaks move, either from one country to another or within a country, clinical trial managers must partner with different hospitals to recruit patients. Only those trial sponsors that are strong enough to form relationships with multiple hospitals will be able to accrue large numbers of patients for their trials. suggests that pulmonary fibrosis in COVID-19 survivors is a new opportunity for MSC therapy, and may be the most feasible and effective application of MSC to Coronavirus.

Despite COVID-19, nearly 30% more advanced cell therapy trials were registered during 2020 Q1 than in the previous year. The fraction of the non-COVID-19 trials that are recruiting is about the same as last year.

We present a table that compares media coverage in the western hemisphere versus clinical trial registration for cell therapy companies that propose to treat some aspect of COVID-19. During this time of upheaval, some companies are bypassing the normal trial registration process and entering clinical applications based on Compassionate Use Exemptions or  Emergency Use Authorizations. reveals that none of the previous clinical trials of MSC for ARDS were able to demonstrate efficacy. Companies rushing to treat COVID-19 patients with MSC are hyping their potential.

We forecast that CAR-immunotherapy sourced from universal donors is a growth field. The use of donor cells eliminates the patient apheresis step and the associated time delay to wait for autologous cells to be converted to CAR cells.

The number of CAR immunotherapy trials have risen 25-fold over the past decade. Clinical trials with some type of T-cells accounted for 70% of all immunotherapy clinical trials in 2019.

From 2018 to 2019 there was very little growth in the total number of newly registered advanced cell therapy clinical trials. We interpret this stabilization of growth as a sign that the field of cell and gene therapy is maturing. is the only clinical trials compilation that captures Chinese cell therapy trials registered on both and ChiCTR. Our unique database enables us to find trends not reported elsewhere.

The first half of 2019 has seen a significant jump in the number of cell therapy trials for osteoarthritis (OA), particularly in large and late phase clinical trials. We review the data from 5.5 years of osteoarthritis clinical trials and describe the leading trials.